BGL announces the sale of Lowenco to Impilo and SHS
CHICAGO, February 3, 2022 /PRNewswire/ — Brown Gibbons Lang & Company (BGL), a leading investment bank and financial advisory firm, is pleased to announce the sale of Lowenco A/S (Lowenco), a leading manufacturer of storage ultra-low temperature (ULT) solutions for the pharmaceutical industry, at Impilo and SHS. BGL’s Healthcare & Life Sciences investment banking team initiated the transaction and acted as exclusive financial advisor to Lowenco. Specific terms of the transaction were not disclosed.
BGL’s Healthcare & Life Sciences team initiated the transaction and acted as exclusive financial advisor to Lowenco.
Founded in 2013 and based in Vamdrup, Denmark, Lowenco is a leading manufacturer of large-scale ULT storage solutions for biotechnology and pharmaceutical companies. The company’s unique modular solutions have been developed under the LSSU and CON20 brands, with an ever-expanding R&D pipeline and growing global customer base. Lowenco supplies its customized solutions worldwide, wherever GMP guidelines are followed.
The company is well positioned to continue to meet the growing demand for large-scale ULT storage solutions, underpinned by strong underlying biopharmaceutical volume growth, by leveraging its unique customer value proposition centered on quality, superior performance and service, leading cost of ownership and energy efficiency. Following the transaction, Lowenco’s management team will remain intact, led by CEO Mikael Hoierwho has been part of the management team since 2017.
Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies active in pharmaceuticals, medical technology, healthcare services and other healthcare-related fields. The acquisition of Lowenco marks Impilo’s fourth investment in Denmark. SHS, based in Tübingen, Germanyspecializes in investments in the healthcare sector and is currently investing from its fifth fund, launched in 2018.
BGL’s healthcare and life sciences team has decades of experience advising companies on diagnostics, research tools, laboratory equipment and devices. We have provided capital formation, technology strategy, ventures, and medical device M&A strategy for a wide range of companies. Additionally, we maintain active relationships with global industry players and capital providers, and closely monitor regulatory and reimbursement trends. Our involvement in the industry not only enables us to provide unique access to capital providers, but also to identify and execute strategic opportunities for our investment banking clients.
About Brown Gibbons Lang & Company
Brown Gibbons Lang & Company (BGL) is a leading independent investment bank and financial advisory firm focused on the global middle market. The firm advises private and public companies and private equity groups on mergers and acquisitions, capital markets, financial restructurings, valuations and opinions, and other strategic matters. BGL has investment banking offices in Chicago, Clevelandand philadelphia creamand real estate agencies in Chicago, Clevelandand San Antonio. The firm is also a founding member of Global M&A Partners, enabling BGL to serve clients in over 30 countries around the world. Securities transactions are conducted through Brown, Gibbons, Lang & Company Securities, Inc., an affiliate of Brown Gibbons Lang & Company LLC and a registered broker-dealer and member of FINRA and SIPC. For more information, visit www.bglco.com.
View original content to download multimedia: https://www.prnewswire.com/news-releases/bgl-announces-the-sale-of-lowenco-to-implilo-and-shs-301475389.html
SOURCE Brown Gibbons Lang & Company